Topical difluprednate monotherapy for uveitic macular edema

Richard J Symes; Farzin Forooghian

doi:10.1016/j.jcjo.2015.10.007

Topical difluprednate monotherapy for uveitic macular edema

Can J Ophthalmol. 2016 Feb;51(1):47-9. doi: 10.1016/j.jcjo.2015.10.007.

Authors

Richard J Symes¹, Farzin Forooghian²

Affiliations

¹ Department of Ophthalmology, University of British Columbia, Vancouver, BC.
² Department of Ophthalmology, University of British Columbia, Vancouver, BC. Electronic address: farzin.forooghian@gmail.com.

PMID: 26874159
DOI: 10.1016/j.jcjo.2015.10.007

Abstract

Objective: To describe the use of topical difluprednate for the treatment of uveitic macular edema.

Design: Retrospective review of 3 consecutive cases of uveitic macular edema.

Methods: Patients were treated with topical difluprednate monotherapy.

Results: All patients experienced complete resolution of uveitic macular edema within 2-4 weeks. We observed a statistically significant improvement in central subfield macular thickness (p = 0.04). There was an overall improvement in visual acuity, but this result was not statistically significant (p = 0.33).

Conclusions: Topical difluprednate can be effective for uveitic macular edema. Further investigation of this therapy in prospective randomized controlled trials is warranted.

Publication types

Case Reports

MeSH terms

Administration, Topical
Adult
Female
Fluprednisolone / analogs & derivatives*
Fluprednisolone / therapeutic use
Glucocorticoids / therapeutic use*
Humans
Macular Edema / diagnosis
Macular Edema / drug therapy*
Macular Edema / physiopathology
Male
Ophthalmic Solutions
Retrospective Studies
Tomography, Optical Coherence
Uveitis, Anterior / diagnosis
Uveitis, Anterior / drug therapy*
Uveitis, Anterior / physiopathology
Uveitis, Intermediate / diagnosis
Uveitis, Intermediate / drug therapy*
Uveitis, Intermediate / physiopathology
Visual Acuity / drug effects

Substances

Glucocorticoids
Ophthalmic Solutions
Fluprednisolone
difluprednate